Company Overview
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $123.67M (+63.5% YoY); net profit $-38.63M.
- Trailing 12 Months Year-on-year growth — revenue -95.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -95.00% |
Stock Price Performance
| 1 Year: | +345.06% |
| 6 Months: | -1.31% |
| 3 Months: | +33.77% |
| 1 Month: | +28.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLUE Monte Rosa Therapeutics, Inc. R2K | 23.41 | -15.82 | $1.98B | 0.00% | -14.10% | -32.62% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.06M | 4.70M | 9.22M | 84.93M | 23.19M | 12.77M | 4.21M |
| Operating Income | - | -5.40M | -6.39M | -11.50M | -18.12M | -19.87M | -24.30M | -27.23M | -28.36M | -34.26M | -37.22M | -36.97M | -34.95M | -32.64M | -26.53M | 44.04M | -15.55M | -32.98M | -50.03M |
| Net Income | -4.30M | -5.36M | -6.56M | -12.28M | -18.41M | -19.84M | -23.93M | -26.47M | -27.32M | -32.04M | -35.18M | -34.88M | -31.97M | -30.31M | -23.86M | 46.88M | -12.29M | -27.08M | -44.50M |
| R&D Expense | - | 4.86M | 5.47M | 9.27M | 14.64M | 15.12M | 17.91M | 20.94M | 21.34M | 26.75M | 29.08M | 28.31M | 27.03M | 28.05M | 27.62M | 32.19M | 30.65M | 36.68M | 44.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 75.62M | 123.67M |
| Operating Income | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M | -54.21M |
| Net Income | -35.88M | -73.96M | -108.50M | -135.35M | -72.70M | -38.63M |
| R&D Expense | 24.00M | 57.16M | 85.06M | 111.27M | 121.56M | 141.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 49.38M | 366.33M | 342.39M | 303.75M | 438.73M | 448.66M |
| Total Equity | -48.73M | 347.51M | 271.41M | 179.25M | 222.94M | 233.06M |
| Cash & Equivalents | 41.70M | 346.07M | 54.91M | 128.10M | 224.25M | 129.88M |
| Total Liabilities | 30.34M | 18.81M | 70.98M | 124.50M | 215.80M | 215.60M |
| Current Liabilities | 29.27M | 16.64M | 25.57M | 46.59M | 156.95M | 64.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.05M | -59.36M | -92.47M | -43.80M | 42.00M | -22.80M |
| Investing Cash Flow | -3.39M | -9.65M | -219.22M | 88.80M | -44.45M | -101.83M |
| Financing Cash Flow | 60.06M | 377.56M | 20.47M | 27.49M | 98.89M | 30.35M |
| Capital Expenditure | -3.39M | -9.73M | -12.91M | -19.04M | -3.99M | -4.70M |
| Free Cash Flow | -26.44M | -69.09M | -105.38M | -62.84M | 38.01M | -27.50M |
| Dividends Paid | - | 0 | 0 | 0 | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -107.3% | -43.8% |
| Net Margin % | - | - | - | - | -96.1% | -31.2% |
| ROE % | 73.6% | -21.3% | -40.0% | -75.5% | -32.6% | -16.6% |
| ROCE % | -139.3% | -20.8% | -35.5% | -55.7% | -28.8% | -14.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.11% | 7.69M | $180.46M |
| 2 | Price (T.Rowe) Associates Inc | 7.95% | 6.72M | $157.66M |
| 3 | Blackrock Inc. | 6.67% | 5.64M | $132.26M |
| 4 | TCG Crossover Management, LLC | 5.47% | 4.62M | $108.44M |
| 5 | BVF Inc. | 5.28% | 4.46M | $104.65M |
| 6 | Baker Bros. Advisors, LP | 5.14% | 4.35M | $101.95M |
| 7 | Suvretta Capital Management, LLC | 5.00% | 4.23M | $99.16M |
| 8 | Vestal Point Capital, LP | 4.27% | 3.60M | $84.54M |
| 9 | State Street Corporation | 3.97% | 3.35M | $78.68M |
| 10 | Braidwell LP | 3.80% | 3.21M | $75.23M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLUE
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOOGo4WEY1Wkx5ekc2WkFlZGlTQWZVYXU3eVBCdmNZLXUxUEpiSFJaNzVfLXJmLU44bkR6Y1RjSEpMSkREMEtoODhSQlN2bnAxY1NtcW5VOVNDOEJCTHlzOGkzS0liV000Qnd5ZXB5TEZjS2Y1b1dHSzBnV2ZZSmlDcWpjZHpPNVVzMDNRUl…
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUG5ydUdlZU9TYkEzNG5NVkNFSno1ek5ra01RQ3pOeW9XVENzQjVKN1ZtMGRMeGpVeGFlS0RZZU5tZEpSbUd6TUxHSXcxYmpDOHZYYWxtaFVyX1dRMDFiR0hJUHBPbG5mMnlQb1pIMHhzYXlkbEJfQUFEQ3FIZGdLRjVCZi1LbzgwNG56Nk…
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened - MarketBeat
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQa25ITjM4ZUE5cEpJUHFJbXNEWGdmQi1vZmpWRF9VaFJHb0FLTl9ORHd6cVFNZFdVMVhhd2pXU3hsc1dVY3E5V1FOWkh6U3ZELW5EOE5VWDM4Zy01U0dvbVdJS1Q1ejVJRTJRRGROVmZhS3FNakdZT09CcnJsNnlsY25NNWNnXzRVcUlsTU…
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNeUdady1LTERjVWFOa0FCaUZVbG5LU3RhRjNtOVg2bkdKeXFtNk5qaUxadWJmRFJvTVhHUlluWTFOUEpaVnVqV2VmalIzQkJFX3UyRVN4cDBwdE5fWlo1cmNPblZpc2lXc3Z3bXBSaTF2WUlETDFfUzE5Xzg3OWxWZjVn?oc=5" target=…
Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxQXzUySHJVWHdEWXk3bjNkZnhtbzgwLURzSGh0aVkzTklnX2F5VnYwT0tsX1h3WG85NDBvdllYa2RuRndTS2E1RGJCUkdJNzhZMlNpWWRhXzdES0IxVXlOVXRMZnlQR3MweXpJY1ZDVXU2M1ZHalI0bmZfX2d5dTN6THpueE9jaEpuaGdwVi…
5 molecular glues that could stick—and the companies stuck in - BioSpace
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNbUJqZHBPc0k5cnEtTFREYVh6LVJTdGkxdWV0bnNIMUhkOERXM21MSnJzYUhnREhNYmd2cVRPb2pJYlN5aVZQQklfUFBtb2dSeDJvSU9vdnJqSUtSOEx0YnJybmIwb2kyandBdWl1RGFDbHZSY3ZKcVVub2tEbUlnamIzRGhDOE9jc1V2NG…
GLUE — Frequently Asked Questions
What is the current share price of Monte Rosa Therapeutics, Inc. (GLUE)?
As of 2026-07-15 16:51 PDT, Monte Rosa Therapeutics, Inc. (GLUE) trades at $23.41 on NasdaqGS. Its 52-week range is $4.19 to $25.31.
What is the market capitalisation of GLUE?
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalisation of $1.98B on NasdaqGS.
What is the P/E ratio of GLUE?
GLUE trades at a trailing price-to-earnings (P/E) ratio of -15.82. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 3.79.
What is the return on equity (ROE) of GLUE?
GLUE has a return on equity (ROE) of -32.62%. Its return on capital employed (ROCE) is -14.10%.
Is GLUE a good stock to buy?
This page provides a data-driven analysis of Monte Rosa Therapeutics, Inc. (GLUE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.